University of Hyderabad 
Hyderabad

COVID-19: Hyderabad University, CCMB tie up for antibody therapy

Horse-based antibodies have been used earlier for developing antibody therapy for a variety of life-threatening pathologies in humans as anti-venoms, anti-toxins and anti-virals.

From our online archive

HYDERABAD: The University of Hyderabad (UoH) and Centre for Cellular and Molecular Biology (CCMB) have teamed with a startup incubated at the UoH, namely Vins Bioproducts Ltd, in a collaborative project to develop antibody fragment-based therapy against Covid-19.

They plan to use antibody fragments, synthesised from the antibodies generated in horses, offered by the F(ab’)2 platform technology. 

Horse-based antibodies have been used earlier for developing antibody therapy for a variety of life-threatening pathologies in humans as anti-venoms, anti-toxins and anti-virals.

The antibodies, raised in horses using inactivated Coronavirus is fractionated and purified to produce antibody fragments F(ab’)2 for neutralising Coronavirus in the patients for recovery.

While the UoH team is headed by Dr Nooruddin Khan, Associate Professor at the Department of Animal Biology, the team at CCMB is headed by Dr Krishnan Harinivas, a principal scientist.

Kharge demands CEC's removal, PM's resignation; seeks voter appeal rights, time-bound probe at CWC meet

Asian Games 2026: Shooter Neeru ends India's wait, bags historic gold in trap discipline

One Assam Rifles jawan killed, four injured in suspected militant attack in Arunachal's Changlang district

Jaishankar flags US lack of understanding on cross-border terror concerns, says it impacts bilateral ties

SC to hear plea raising doubts over CEC Gyanesh Kumar's decisions next week